## **GENERAL INFORMATION**

Organizer Christian Dejaco, Bruneck, Italy and Medical University Graz, Austria

Christina Duftner, Medical University Innsbruck, Austria

pdl - Dr. Eugen Preuß, Andreas-Hofer-Straße 6 EG, Innsbruck, Austria **PCO** 

AC Hotel Innsbruck, Salurner Strasse 15, 6020 Innsbruck, Austria Venue

Language English

This course/meeting has been scientifically endorsed by EULAR. Note

Registration fee (in Euros)	Scientific program only		Complete package (incl. 1 night accomodation)	
	until May 30	after May 30	until May 30	after May 30
Medical Specialists	300	400	460	560
Physicians in training	200	300	360	460
Student or post-doc	100	150	260	310

Registration fee includes participation in the whole scientific program, conference material, all coffee breaks, lunch and welfare

## **Discount**

If you also participate in the "6th European Large Vessel Vasculitis Imaging Course", which will take place at the same location from October 3 to 5, 2024, you will receive a 15% discount on both conferences after the events.

For details please visit <a href="https://www.eulvic.eu">https://www.eulvic.eu</a>

Call for abstracts (Deadline: 30th May 2024, 23:59 CET)

We invite you to submit a scientific abstract or a case report to the international LVV-PMR conference 2024 in Innsbruck. Abstracts/Case reports accepted for Poster or Oral Presentation have to be presented on-side, no virtual presentation will be possible.

All abstracts will be peer-reviewed. Among accepted and on-side presented abstracts/case reports, 3 abstract awards and 1 case report award will be nominated. This will be based on the scientific content and quality of presentation. Please find detailed informations on the abstract/case report submission guidelines on our homepage <a href="https://www.lvv-pmr.eu">https://www.lvv-pmr.eu</a>!

Accreditation We will claim CME credits (ECMEC®s) from the European Accreditation

Council for Continuing Medical Education (EACCME®), as well as

educational points (DFP) from the Austrian Medical Chamber.



## October 2 - 3, 2024 | Innsbruck, Austria







	ENDORSED COURSE			
Tuesday, October 2, 2024  08.30 Welcome C. Dejaco				
08.30 Welcome	C. Dejaco			
08.35-10.30 Epidemiology and public health				
From history to future: Who was the first LVV patient and what	S. Mackie			
will be the impact of LVV/PMR in 2030 to society?	o. madino			
Artificial intelligence in LVV - the future starts right now!	V. Schäfer			
Aneurysms in LVV: What does it mean for morbidity and mortality? How to manage?	K. Warrington			
Discussion:	M. Bond and			
Is there a seasonal clustering of LVV and PMR?	W. Schmidt			
11.00-13.00 Pathophysiology				
Genetics in LVV	A. H. Sawalha			
Immune aging and aging tissue: Cause or consequence of GCA and PMR?	C. Weyand			
Somatic mutations versus virus hypothesis: What is the real trigger for LVV?	J. Thiel			
Understanding pathophysiology of TAK and isolated aortitis –	C.			
What are the commonalities and differences to GCA?	Campochiaro			
What causes PMR: Autoimmunity or autoinflammation?	E. Brower			
14.00-16:00 Meet the Professor-Workshops (max. 10 per gro	oup, 1 rotation)			
GCs and immunosuppressants in the long-term	T. Kermani			
How to construct a fast-track pathway	A. Diaman- topoulos			
Challenging cases in GCA and PMR	M. Cid			
Challenging cases in TAK/isolated aortitis	G. Hatemi			
Imaging in PMR	W. Schmidt			
Defining relapse of LVV and PMR: research and real-word experiences	S. Mackie			
IgG4 and other orphan diseases associated with LVV	C. Salvarani			
Early referral and shared care between specialist and primary care in PMR	K. Keller			
Vascular ultrasound: Temporal arteries	A. Hocevar			
Vascular ultrasound: Extra-cranial large arteries	C. Duftner			
Pregnancy and fertility in patients with LVV	F. Alibaz-Oner			
Escape room: find the last bottle of cortisone	M. Reisch, D. Kickinger			

What does th Opthtalmolog	S. P. Mollan, F. Esen	
Neurologist: I	K. Chinthapalli	
When do we	need vascular interventions in patients with LVV ne prognosis?	D. Danda
What have we	e learned from patients about LVV and PMR?	J. Robson
18.30-19.00	Satellite Symposium	TBN
	Wednesday, October 3, 2024	
08.00-10.30	Treatment of LVV and PMR (1)	
Current treatr	ment recommendations in GCA and PMR	B. Hellmich
Current treatr	ment (recommendations) of TAK and other LVV	H. Direskeneli
Takayasu arte		D. Camellino, T. Sugihara
	C treatment in LVV and PMR:	J. Stone
	e long-term low dose GCs?  uld we still use conventional immunosuppressives  MR?	R. Luqmani, S. Sattui
11.00	Presentation of selected abstracts and best abstra	ct award
12.00	<b>Lunch debate</b> moderated by B. Dalsgaard Nielsen 8 Incidental LVV in pure PMR: treat as GCA or PMR?	• •
13.30-15.30	Treatment of LVV and PMR (2)	
Trials in LVV	that have failed – what can we learn from it?	C. Mukhtyar
Management	of cardiovascular risk and comorbidities in LVV	S. Unizony
New biomark	A. Tomelleri	
	urrent drug trials - he next drugs on the market?	F. Buttgereit
16.10-18.40	Imaging in the diagnosis and monitoring	of LVV
Imaging for th	ne diagnosis of LVV: international recommendations	C. Dejaco
Imaging for m	L. Seitz	
Imaging for m	S. Monti	
other rheuma		C. Ponte
Acute versus		
Histopatholog vasculitis	gic findings and clinical correlations in large vessel	A. Cavazza
Concluding ren	narks and welfare	

LVV interdisciplinary

16.30-18.30